These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3145266)

  • 21. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta-lactamase induction and aminoglycoside susceptibility in Pseudomonas aeruginosa.
    Stratton CW; Weeks LS; Tausk F
    J Antimicrob Chemother; 1987 Jan; 19(1):21-5. PubMed ID: 3104276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-vitro activity of imipenem and amikacin combinations against resistant Pseudomonas aeruginosa.
    Fujita J; Negayama K; Takigawa K; Yamagishi Y; Yamaji Y; Kawanishi K; Takahara J
    J Antimicrob Chemother; 1993 Jun; 31(6):1007-9. PubMed ID: 8360119
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of imipenem and five other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa.
    Gerçeker AA; Otük G
    Chemotherapy; 1995; 41(5):334-6. PubMed ID: 8521734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical surveillance of surgical imipenem-resistant Pseudomonas aeruginosa infection in a Japanese hospital.
    Sasaki M; Hiyama E; Takesue Y; Kodaira M; Sueda T; Yokoyama T
    J Hosp Infect; 2004 Feb; 56(2):111-8. PubMed ID: 15019222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa.
    Carmeli Y; Eichelberger K; Soja D; Dakos J; Venkataraman L; DeGirolami P; Samore M
    J Clin Microbiol; 1998 Feb; 36(2):595-7. PubMed ID: 9466787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of various technics in the determination of sensitivity of Pseudomonas aeruginosa to imipenem].
    Maugein J; Fourche J; Pellegrin JL; Mormède M
    Pathol Biol (Paris); 1990 May; 38(5):362-5. PubMed ID: 2114605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].
    Yamashiro Y; Ogake N; Takahata M; Minami S
    Jpn J Antibiot; 2000 Apr; 53(4):194-200. PubMed ID: 10868299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa.
    Higgins PG; Fluit AC; Milatovic D; Verhoef J; Schmitz FJ
    J Antimicrob Chemother; 2002 Aug; 50(2):299-301. PubMed ID: 12161417
    [No Abstract]   [Full Text] [Related]  

  • 32. Microbiological and epidemiological characterization of imipenem-resistant Pseudomonas aeruginosa strains from a Brazilian tertiary hospital: report from the SENTRY Antimicrobial Surveillance Program.
    Ribeiro J; Mendes RE; Domingos R; França E; Silbert S; Jones RN; Sader HS
    J Chemother; 2006 Oct; 18(5):461-7. PubMed ID: 17127220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
    Livermore DM; Yang YJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
    Naenna P; Noisumdaeng P; Pongpech P; Tribuddharat C
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of cross-resistance to imipenem and other beta-lactam antibiotics in Pseudomonas aeruginosa during therapy.
    Pagani L; Landini P; Luzzaro F; Debiaggi M; Romero E
    Microbiologica; 1990 Jan; 13(1):43-53. PubMed ID: 2155376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms responsible for imipenem resistance among Pseudomonas aeruginosa clinical isolates exposed to imipenem concentrations within the mutant selection window.
    Vassilara F; Galani I; Souli M; Papanikolaou K; Giamarellou H; Papadopoulos A
    Diagn Microbiol Infect Dis; 2017 Jul; 88(3):276-281. PubMed ID: 28434899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.
    Shaaban MI; Shaker MA; Mady FM
    J Nanobiotechnology; 2017 Apr; 15(1):29. PubMed ID: 28399890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa.
    Satake S; Yoneyama H; Nakae T
    J Antimicrob Chemother; 1991 Aug; 28(2):199-207. PubMed ID: 1778851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.